Nimocal30 mg

Nimocal is a dihydropyridine calcium channel blocker that is FDA-approved for a single, well-defined indication in neurocritical care.

Established (FDA-approved) indication

• Aneurysmal subarachnoid hemorrhage (SAH): Nimocal is indicated to improve neurological outcome by reducing the incidence and severity of ischemic neurological deficits (cerebral vasospasm-related) in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, regardless of the patient's post-ictus neurological grade (Hunt and Hess Grades I-V).

Nimocal does not reverse or reduce the angiographic vasospasm itself; its clinical benefit is on neurological outcome. Treatment should be started within 96 hours of the onset of subarachnoid hemorrhage and requires a physician's supervision in a hospital setting. There is no well-established, guideline-supported role for Nimocal outside this indication, and off-label use should only occur under direct specialist guidance.

Each soft gelatin capsule contains Nimodipine 30 mg as the active ingredient. Nimodipine is also available in some markets as an oral solution. In Bangladesh, Nimodipine is marketed as 30 mg oral capsules/tablets.

Nimocal is a dihydropyridine-class calcium channel blocker that, unlike most other agents in its class, is used specifically for its effect on the cerebral vasculature rather than for blood pressure control. It is highly lipophilic, which allows it to cross the blood-brain barrier and reach the cerebrospinal fluid.

Nimocal is used exclusively in the hospital setting to reduce ischemic neurological deficits following aneurysmal subarachnoid hemorrhage. It is administered strictly by the oral or enteral route; it must never be given intravenously.

Nimocal belongs to the calcium channel blocker (CCB) class, specifically the dihydropyridine subgroup. Within this subgroup, Nimocal is distinguished by its relatively selective action on cerebral (rather than systemic) blood vessels, which is why it is used in neurology/neurosurgery rather than as an antihypertensive.

Pharmacodynamics

Nimodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle cells, producing relaxation of cerebral blood vessels. The precise mechanism by which this translates into improved neurological outcome after subarachnoid hemorrhage has not been fully established, but Nimodipine reduces the incidence and severity of ischemic deficits without necessarily reversing angiographic vasospasm.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral dosing, with peak plasma concentration reached within about 1 hour; a standard meal can reduce peak concentration and overall bioavailability substantially, so Nimodipine is best taken apart from food.
• Distribution: More than 95% bound to plasma proteins; high lipophilicity allows penetration into the cerebrospinal fluid.
• Metabolism: Undergoes extensive first-pass hepatic metabolism via the CYP3A4 enzyme system, giving an average oral bioavailability of only about 13%.
• Elimination: Eliminated almost entirely as metabolites, mainly via bile/feces with a smaller renal component; effective half-life is short (roughly 1-2 hours), which is why frequent (every 4 hour) dosing is required despite a longer terminal half-life.

Nimocal must be taken by mouth or via a feeding tube only — never intravenously. Take on an empty stomach (1 hour before or 2 hours after food) with a little liquid. If the patient cannot swallow, a physician or nurse may withdraw the liquid contents through a needle and give the dose via a nasogastric tube, flushing afterward with saline.

Clinically Significant Interactions

• Strong CYP3A4 inhibitors (e.g. certain macrolide antibiotics, azole antifungals, HIV protease inhibitors, nefazodone): markedly raise Nimocal plasma levels, greatly increasing the risk of severe hypotension. Concurrent use is contraindicated — see Contraindications.
• Strong CYP3A4 inducers (e.g. rifampin, phenobarbital, phenytoin, carbamazepine): can substantially reduce Nimocal plasma levels and efficacy; concurrent use should generally be avoided.
• Other antihypertensive agents or vasodilators: may have an additive blood-pressure-lowering effect when combined with Nimocal; blood pressure should be monitored closely.
• Grapefruit juice: inhibits intestinal CYP3A4 metabolism and can raise Nimocal levels for several days after ingestion; it should be avoided during treatment.

The most common adverse effect of Nimocal is a drop in blood pressure. Because subarachnoid hemorrhage itself often alters consciousness, some adverse effects may be under-reported in affected patients.

Common

• Decreased blood pressure (most frequently reported)
• Headache
• Nausea
• Diarrhea
• Rash
• Edema (fluid retention/swelling)
• Abnormal liver function test results
• Bradycardia (slow heart rate)

Uncommon/Rare

• Intestinal pseudo-obstruction or ileus (reduced bowel motility) — usually managed conservatively; report severe abdominal distension or constipation promptly.

Pregnancy

Nimocal should be used during pregnancy only if clearly needed, and only if the potential benefit to the mother justifies the potential risk to the fetus. Animal studies have shown adverse fetal effects at high doses; adequate, well-controlled studies in pregnant women are lacking. A physician should always be consulted before use in pregnancy.

Breastfeeding

It is not known whether Nimocal passes into human breast milk, but related compounds have been detected in animal milk at levels exceeding those in maternal blood. Because of the potential for adverse effects in a nursing infant, a decision should be made in consultation with a physician about whether to discontinue breastfeeding or discontinue Nimocal, taking into account the importance of the medicine to the mother.

Route of administration warning

Nimocal must be given by the oral or enteral route only. Intravenous or other parenteral administration is contraindicated and has resulted in death and serious harm — see Contraindications.

Hypotension

Nimocal can lower blood pressure, particularly in patients already receiving other antihypertensive medicines. Blood pressure and heart rate should be monitored regularly during treatment, especially at initiation and after dose changes.

Hepatic impairment

Patients with liver disease (e.g. cirrhosis) metabolize Nimocal more slowly, leading to higher blood levels; a reduced dose and closer monitoring of blood pressure and heart rate are required — see Dosage and Administration.

Gastrointestinal effects

Rarely, Nimocal has been associated with intestinal pseudo-obstruction or ileus. Report persistent abdominal distension, severe constipation, or vomiting to a physician promptly.

General

Nimocal should only be used under the supervision of a physician experienced in the management of subarachnoid hemorrhage, typically in a hospital setting.

No cases of oral overdose with Nimocal have been well documented, but an overdose would be expected to cause excessive vasodilation leading to marked, sustained low blood pressure and a reflex increase or decrease in heart rate.

If an overdose of Nimocal is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive and may include intravenous fluids and vasopressor medicines to maintain blood pressure under close medical supervision; because Nimocal is highly protein-bound, dialysis is not expected to be effective. Do not attempt to manage a suspected overdose at home.

Store between 20°C and 25°C (68°F-77°F) in the original packaging, protected from light and from freezing. Keep out of reach of children.

Pregnancy and lactation

Use only if clearly needed — see Pregnancy and Lactation section above.

Pediatric use

Safety and efficacy of Nimocal in pediatric patients have not been established.

Geriatric use

Elderly patients (studied at 59-79 years) have shown roughly two-fold higher Nimocal blood levels than younger adults; the clinical significance is not fully established, but Nimocal should be used with caution in elderly patients, taking into account age-related decreases in hepatic, renal, and cardiac function.

Hepatic impairment

Bioavailability of Nimocal is increased in patients with liver cirrhosis; a reduced dose (30 mg every 4 hours) with close monitoring is recommended — see Dosage and Administration.

Renal impairment

Less than 1% of a Nimocal dose is excreted unchanged in urine; no specific dose adjustment is established for renal impairment, but Nimocal should still be used with appropriate monitoring in these patients.

The standard course of Nimocal for subarachnoid hemorrhage is 21 consecutive days, started within 96 hours of the onset of hemorrhage. The duration should not be shortened or extended except on a physician's advice.

Calcium channel blockers; Dihydropyridine derivatives

Nimodipine blocks the influx of calcium ions through voltage-gated (L-type) calcium channels in vascular smooth muscle cell membranes. By reducing intracellular calcium entry, it relaxes cerebral blood vessels. Its high lipophilicity allows it to cross the blood-brain barrier and act preferentially on the cerebral vasculature. The exact link between this action and the observed improvement in neurological outcome after subarachnoid hemorrhage is not completely understood, since Nimodipine improves outcomes without necessarily relieving angiographic vasospasm.

C

The safety and efficacy of Nimocal have not been established in pediatric patients. Nimocal is not recommended for use in children outside of specialist, investigational settings, and should only be considered in a child if a physician determines the potential benefit clearly outweighs the unknown risks.